Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Key Takeaways Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

Here are some of the biggest premarket U.S. stock movers today: Palo Alto Networks (NASDAQ: PANW) stock rose 0.4%, with the ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk A/S innovation and growth continue to shine. Now, it has a partnership with GoodRX Holdings. Click for my ...

Eli Lilly & Novo Nordisk target cash-pay customers in the GLP-1 weight loss market with $499 monthly offers. Read more here.

Novo Nordisk is working with GoodRx to offer a month’s supply of Ozempic for $499, or about half the list price, for self-paying patients.  Ozempic, a drug approved for Type 2 diabetes, cardiovascular ...

GoodRx Stock Spikes 35% on Novo Nordisk Collaboration. They’re Offering Ozempic for $499 a Month.